- Conditions
- Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Chemotherapy, Metastasectomy
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1417–1440
of 2,360
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer
- Interventions
- oxaliplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
- Interventions
- Sulindac, Placebo, Validate assays and shipping methods
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Erlotinib and capecitabine
- Drug
- Lead sponsor
- Peter Kozuch
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Microsatellite Instability High, Mismatch Repair Deficiency, Colorectal Cancer
- Interventions
- RT and Anti-PD-1, Anti-PD-1
- Combination Product · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
- Interventions
- Talimogene Laherparepvec, Atezolizumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Stony Brook, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, Nivolumab, Ipilimumab, GVAX Pancreas Vaccine, CRS-207
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- Celecoxib, Gemcitabine Hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 11
- States / cities
- Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 8 more
- Conditions
- Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer, Cholangiocarcinoma, Duodenal Cancer, Colorectal Cancer, Small Bowel Cancer, Metastatic Cancers
- Interventions
- KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cholangiocarcinoma
- Interventions
- Nab-Paclitaxel and Gemcitabine
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 24
- States / cities
- Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- ZN-c3, Encorafenib, Cetuximab
- Drug
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Merriam, Kansas • Houston, Texas
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
- Interventions
- XB002, Nivolumab, Bevacizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Interventions
- RAD001, Cetuximab, Irinotecan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 16
- States / cities
- Fayetteville, Arkansas • Bakersfield, California • La Jolla, California + 13 more
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Malignant Brain Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Skin Carcinoma
- Interventions
- Biospecimen Collection, Genetic Testing
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida
- Conditions
- Colorectal Neoplasms, Diarrhea
- Interventions
- Investigational drug, Irinotecan, 5-fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more
- Conditions
- Colorectal Cancers
- Interventions
- RENCA macrobeads
- Biological
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Westwood, Kansas • New York, New York • The Bronx, New York + 1 more
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- Initiation of trifluridine-tipiracil plus bevacizumab, Initiation of trifluridine-tipiracil alone
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Somerville, Massachusetts
- Conditions
- Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
- Interventions
- BKM120, mFOLFOX6
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Colorectal Cancer, Liver Metastases
- Interventions
- Not listed
- Lead sponsor
- Andrew Kennedy
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Colorectal Cancer, Metastases
- Interventions
- Cetuximab, Bevacizumab, Leucovorin, Oxaliplatin, Fluorouracil
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Neoplasms
- Interventions
- ADH300004
- Drug
- Lead sponsor
- Adherex Technologies, Inc.
- Industry
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancers, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer, CDH17-positive Advanced Solid Tumors, Advanced Gastric Cancer
- Interventions
- BHB810
- Drug
- Lead sponsor
- BigHat Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • Santa Monica, California • Fairfax, Virginia
- Conditions
- Colon Cancer
- Interventions
- Non-interventional
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico